Focusing on Improving Patient Outcomes for Serious Unmet Medical Needs
Latest News
News / 08 Jun 2021
Summit Therapeutics set to join Russell 3000® Index
News / 03 Jun 2021
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
News / 18 May 2021
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.
Chairman & Chief Executive Officer
Partners
BARDA
Summit is proud to partner with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), as initially announced on September 11, 2017, on its two Phase III pivotal trials, Ri-CoDIFy 1 & 2, investigating ridinilazole for the treatment and reduction of recurrence of C. difficile infection.
CARB-X
Summit is proud to partner with CARB-X, as announced on May 18, 2021, to progress the development of its precision antibiotic candidate, SMT-738, through its IND-enabling and Phase Ia clinical trials for the treatment of highly-resistant CRE bacterial infections.